Henry Schein
HSIC
$73.80
-3.05%
Henry Schein Inc is a leading solutions company for healthcare professionals, operating in the Medical Distribution industry by providing healthcare equipment, products, and services to office-based dental and medical practitioners. The company is a dominant market leader in the healthcare distribution space, distinct for its integrated model that combines distribution with value-added services like financial services, consulting, and technology solutions. The current investor narrative centers on its post-cyberattack recovery and operational normalization, as evidenced by recent quarterly revenue growth, alongside ongoing strategic focus on expanding its higher-margin Technology and Specialty Products segments to drive future profitability.…
HSIC
Henry Schein
$73.80
Investment Opinion: Should I buy HSIC Today?
Rating & Thesis: The recommendation is HOLD. HSIC is a stable, cash-generative market leader in recovery, but its current price fairly reflects the near-term growth trajectory and leaves limited margin of safety for new capital. This aligns with the analyst consensus of Neutral.
Supporting Evidence: The stock trades at a forward P/E of 13.2x, which is reasonable but not deeply discounted for a company with mid-single-digit revenue growth. Q4 revenue growth of 7.71% is positive but shows signs of sequential deceleration. Profitability is stable but not expanding, with a TTM operating margin of 5.75%. The strong TTM Free Cash Flow of $561 million and ongoing buybacks provide a floor for the stock, but these are already appreciated by the market.
Risks & Conditions: The two biggest risks are a failure to accelerate growth post-recovery and valuation compression from its elevated trailing P/E. This Hold would upgrade to a Buy if the forward P/E compressed below 11x (offering a clearer margin of safety) or if quarterly revenue growth re-accelerated sustainably above 10%. It would downgrade to a Sell if revenue growth turned negative or if the stock broke below its 52-week low of $61.95 on deteriorating fundamentals. Relative to its history and sector peers, the stock is fairly valued, trading between its depressed earnings past and its hoped-for earnings future.
Sign up to view all
HSIC 12-Month Price Forecast
The outlook for HSIC is one of stabilized recovery rather than explosive growth. The base case is most probable, with the stock likely to trade sideways to slightly higher as it grinds towards its earnings targets. The key upside lever is margin expansion from its strategic segments, while the key downside risk is a growth stall. The stance would upgrade to Bullish on confirmation of sustained margin improvement (gross margin >30%) and revenue growth stabilization above 8%. It would downgrade to Bearish on a breakdown below $75 on high volume coupled with a cut to forward EPS estimates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Henry Schein's 12-month outlook, with a consensus price target around $95.94 and implied upside of +30.0% versus the current price.
Average Target
$95.94
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$59 - $96
Analyst target range
The stock is covered by 7 analysts, and the institutional ratings show a mixed but leaning positive sentiment, with 3 Outperform/Overweight ratings, 3 Neutral/Market Perform ratings, and 1 Underweight rating. The consensus recommendation is therefore Neutral with a bullish tilt. The average target price is not explicitly provided in the data, but analyst estimates point to an average EPS forecast of $6.80 for the coming period. Insufficient analyst coverage available to calculate a precise implied upside or downside to a consensus price target. The target range and specific price targets are not provided in the dataset, which limits the ability to gauge the dispersion of analyst views. The available institutional ratings from February 2026 show no recent changes in the majority of coverage, with only one upgrade (Baird to Outperform from Neutral), indicating generally stable analyst sentiment. The limited number of covering analysts and absence of explicit price targets is typical for a mid-cap stock like HSIC and can contribute to higher volatility and less efficient price discovery compared to heavily covered large-caps.
Bulls vs Bears: HSIC Investment Factors
The evidence presents a balanced but cautiously optimistic picture. The bull case is anchored in strong cash generation, a clear recovery narrative, and an attractive forward valuation. The bear case focuses on decelerating growth momentum, premium trailing valuation, and thin margins. Currently, the bull side has slightly stronger evidence due to the concrete financial recovery (7.71% revenue growth) and compelling forward P/E of 13.2x. The single most important tension in the investment debate is whether the company can transition from a post-cyberattack recovery story to a sustainable growth story, justifying its current valuation before the market's patience for margin expansion and top-line acceleration runs out.
Bullish
- Strong Free Cash Flow Generation: The company generates robust free cash flow, with TTM FCF of $561 million. This provides ample internal funding for strategic initiatives, including the $200 million in stock buybacks executed in Q4 2025, supporting shareholder returns.
- Post-Cyberattack Recovery & Revenue Growth: Q4 2025 revenue grew 7.71% YoY to $3.437 billion, signaling a return to operational normalization. The sequential quarterly revenue growth from $3.168B to $3.437B throughout 2025 demonstrates a steady recovery trajectory.
- Attractive Forward Valuation: The stock trades at a forward P/E of 13.2x, a significant discount to its trailing P/E of 23.1x. This implies the market expects a substantial earnings recovery, making the stock appear reasonably valued on a forward basis.
- Stable Profitability & Market Leadership: The company maintains consistent profitability with a Q4 net margin of 2.94% and a TTM operating margin of 5.75%. Its dominant position in healthcare distribution provides a stable, cash-generative business model.
Bearish
- Decelerating Revenue Growth Momentum: While Q4 revenue grew 7.71% YoY, the quarterly growth rate has moderated from earlier in the year, indicating a normalization trend. This raises questions about the sustainability of top-line acceleration post-recovery.
- Elevated Trailing P/E vs. Sector: The trailing P/E of 23.1x appears elevated for a low-margin distributor, trading at a premium to typical sector multiples. This suggests the stock is pricing in a full recovery, leaving little room for error.
- Thin and Fluctuating Margins: Gross margin of 28.92% and net margin of 2.94% are thin and have shown quarterly fluctuation without a clear expansion trend. This highlights the operational challenges and competitive pressures in the distribution business.
- Technical Consolidation Near Resistance: The stock is trading at 57% of its 52-week range, with 3-month momentum at just +0.43% versus a 6-month surge of +21.46%. This divergence suggests a pause as it approaches major overhead resistance at the 52-week high of $89.29.
HSIC Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 1-year price change of +17.08%. With a current price of $77.54, it is trading at approximately 57% of its 52-week range ($61.95 to $89.29), positioning it in the middle of the band, which suggests a balance between momentum and value after a significant rally. Recent momentum shows a positive but decelerating trend, with a 1-month gain of +4.43% and a 3-month gain of only +0.43%, indicating consolidation after the strong 6-month surge of +21.46%. This divergence, where short-term momentum is flattening against a strong longer-term uptrend, signals a potential pause or digestion phase as the stock approaches overhead resistance. Key technical levels are clearly defined by the 52-week high of $89.29 as major resistance and the 52-week low of $61.95 as support. A breakout above $89.29 would signal a resumption of the bullish trend, while a breakdown below $61.95 would indicate a more significant trend reversal. The stock's beta of 0.882 indicates it is 12% less volatile than the broader market (SPY), which is notable for a healthcare distributor and suggests it may offer relative stability during market swings.
Beta
0.88
0.88x market volatility
Max Drawdown
-16.9%
Largest decline past year
52-Week Range
$62-$89
Price range past year
Annual Return
+11.5%
Cumulative gain past year
| Period | HSIC Return | S&P 500 |
|---|---|---|
| 1m | +1.5% | +12.6% |
| 3m | -0.7% | +2.5% |
| 6m | +16.8% | +4.3% |
| 1y | +11.5% | +28.4% |
| ytd | -3.9% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HSIC Fundamental Analysis
Revenue growth is positive but shows a decelerating sequential trend; the most recent Q4 2025 revenue was $3.437 billion, representing a solid year-over-year growth of 7.71%. However, examining the quarterly sequence from Q1 to Q4 2025 shows revenue grew from $3.168B to $3.437B, but the growth rate has moderated from the double-digit pace seen in earlier recoveries, implying a normalization trend post-special factors. The company is profitable with a Q4 2025 net income of $101 million, translating to a net margin of 2.94%. Gross margin for the quarter was 28.92%, and the trailing twelve-month operating margin is 5.75%, indicating the business operates on thin but stable spreads typical for distribution. Profitability has been consistent, with net income positive in all recent quarters, though margins have shown some quarterly fluctuation without a clear expansion trend. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.14, and the company maintains adequate liquidity with a current ratio of 1.38. Free cash flow generation is strong, with TTM FCF of $561 million, providing ample internal funding for growth initiatives and share repurchases, as evidenced by the $200 million in stock buybacks in Q4 2025. The ROE of 12.27% indicates acceptable returns on shareholder equity, supported by the company's cash-generative model.
Quarterly Revenue
$3.4B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.28%
Latest Quarter
Free Cash Flow
$561000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HSIC Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 23.1x and a forward PE of 13.2x, based on estimated EPS. The significant gap between trailing and forward multiples implies the market expects a substantial recovery in earnings over the next year, likely pricing in the full-year benefit of post-cyberattack normalization and cost management. Compared to sector averages, the trailing PE of 23.1x appears elevated for a low-margin distributor, suggesting the market may be assigning a premium for the company's market leadership, stable cash flows, and technology segment optionality. However, the forward multiple of 13.2x is more in line with value-oriented healthcare stocks. Historically, the stock's own trailing PE has ranged widely; the current 23.1x is above the low end of its historical band seen in 2023 but below the highs above 130x during periods of depressed earnings. This positioning in the mid-to-upper range of its historical valuation suggests the market has priced in a solid recovery but remains cautious about significant multiple expansion from current levels.
PE
23.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 15x~136x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HSIC operates on thin spreads, with a Q4 net margin of only 2.94% and gross margin of 28.92%. This leaves little buffer for cost inflation or competitive pricing pressure. While leverage is moderate with a Debt-to-Equity ratio of 1.14, interest expense of $39 million in Q4 consumes a meaningful portion of operating income ($186 million). Revenue concentration in the low-margin Global Distribution segment creates dependence on volume growth to drive profits, making the business sensitive to any slowdown in dental and medical practitioner spending.
Market & Competitive Risks: The stock's trailing P/E of 23.1x is elevated for a distributor, creating valuation compression risk if earnings growth fails to meet elevated expectations implied by the forward P/E of 13.2x. The stock has significantly underperformed the market, with a 1-year relative strength of -13.5% versus the SPY, indicating sector or company-specific headwinds. As a healthcare distributor, it faces constant competitive pressure from larger peers and direct-to-consumer models, which could further compress its already thin margins over time.
Worst-Case Scenario: The most damaging scenario involves a combination of a growth stall and multiple compression. If revenue growth decelerates below 5% while margins contract due to inflationary pressures, forward EPS estimates would be cut. This could trigger analyst downgrades from the current neutral stance, leading the stock to re-rate towards its 52-week low of $61.95. From the current price of $77.54, this represents a realistic downside of approximately -20%. A breach of that support could see losses extend towards the -30% range, mirroring the stock's historical max drawdown of -16.93% but exacerbated by a loss of investor confidence in the recovery thesis.
FAQ
The key risks are, in order of severity: 1) Growth Deceleration Risk: Revenue growth has moderated sequentially; a stall below 5% would undermine the recovery thesis. 2) Margin Compression Risk: With thin net margins of ~3%, any cost inflation or competitive pricing could significantly impact profits. 3) Valuation Risk: The elevated trailing P/E of 23.1x leaves the stock vulnerable to multiple contraction if forward earnings estimates are cut. 4) Operational Risk: The company is still recovering from a major cyberattack; any recurrence or similar disruption would be severely damaging to operations and investor confidence.
The 12-month forecast centers on a base-case target range of $75 to $85 (60% probability), implying a modest upside from the current price. This scenario assumes the company meets its $6.80 EPS estimate and trades at a stable forward P/E. The bull case (25% probability) targets $85 to $89, driven by margin expansion and faster growth. The bear case (15% probability) sees the stock falling to $62 to $75 if growth disappoints. The most likely outcome is range-bound trading, as the stock has already priced in much of the near-term recovery, requiring new catalysts to break meaningfully higher.
HSIC is fairly valued. Its trailing P/E of 23.1x appears elevated, but this is a distortion from depressed past earnings. The more relevant forward P/E of 13.2x, based on a $6.80 EPS estimate, is in line with value-oriented healthcare stocks and reflects a market expecting a solid earnings recovery but not significant multiple expansion. Compared to its own history, it trades in the mid-to-upper range of its valuation band. The valuation implies the market is paying a fair price for steady, single-digit growth and strong cash generation, but no premium for transformative growth.
HSIC is a reasonable but not compelling buy at current levels. For investors seeking a low-volatility, defensive holding with a steady recovery narrative, it offers a fair entry point with a forward P/E of 13.2x. The implied upside is modest, tied to the stock reaching the upper end of its base-case range ($85), representing roughly 10% appreciation. However, the significant risk is a -20% drawdown to its 52-week low if growth stalls. Therefore, it is a better fit for existing holders or very patient investors comfortable with a Hold rating, rather than a aggressive new purchase.
HSIC is more suitable for a long-term investment horizon of 2-3 years. Its low beta (0.882) and steady business model are not conducive to short-term trading gains. The investment thesis is based on the gradual execution of a multi-year recovery and strategic shift towards higher-margin segments, which will take time to materially impact financials. Short-term traders would be challenged by the stock's recent consolidation and lack of clear near-term catalysts. Long-term investors can benefit from the company's stable market position, cash flow generation, and capital return program while waiting for the growth initiatives to bear fruit.
